hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06283680, orgStudyIdInfo id: 2024, briefTitle: The Effect of Nutrition and BMI on on Lung Capacity, Functional Capacity and Mortality in End-Stage Lung Patients, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-02-28, primaryCompletionDateStruct date: 2024-04-28, completionDateStruct date: 2024-05-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Aylin Seylam Küşümler, class: OTHER, collaborators name: Koşuyolu Yüksek İhtisas Training and Research Hospital, descriptionModule briefSummary: The aim of this study was to investigate the effect of nutritional risk index, BMI and body fat, muscle ratio on functional capacity, lung capacity, exercise capacity index, all-cause mortality, post-transplant intensive care unit stay and survival time in end-stage lung patients on the lung transplant list., conditionsModule conditions: Lung Transplant, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 213, type: ESTIMATED, armsInterventionsModule interventions name: Lung transplantation, outcomesModule primaryOutcomes measure: BMI, secondaryOutcomes measure: Nutrition risk index, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: OkanU, city: Istanbul, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06283667, orgStudyIdInfo id: NN9536-4872, secondaryIdInfos id: U1111-1266-3863, type: OTHER, domain: World Health Organization (WHO), briefTitle: Special Use - Results Surveillance on Long-term Use With Wegovy®, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-22, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2028-01-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Novo Nordisk A/S, class: INDUSTRY, descriptionModule briefSummary: The purpose of the study is to investigate the safety and effectiveness of Wegovy® in patients with obesity disease under real-world clinical practice in Japan. Participants will get Wegovy® as prescribed by the study doctor. The study will last for about 4 years. Participant will be in the study for about 2 years (104 weeks)., conditionsModule conditions: Obesity, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Semaglutide, outcomesModule primaryOutcomes measure: Number of Adverse Reactions (ARs), secondaryOutcomes measure: Number of Adverse Events (AEs), secondaryOutcomes measure: Number of serious adverse events (SAEs), secondaryOutcomes measure: Number of Serious Adverse Reactions (SARs), secondaryOutcomes measure: Change in body weight (Percent (%)), secondaryOutcomes measure: Change in body weight (Kilograms (Kg)), secondaryOutcomes measure: Change in waist circumference, secondaryOutcomes measure: Change in BMI (Body Mass Index), secondaryOutcomes measure: Change in body weight after treatment discontinuation, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Novo Nordisk Investigational Site, city: Tokyo, state: Chiyoda City, zip: 100-0005, country: Japan, geoPoint lat: 35.6895, lon: 139.69171, hasResults: False
protocolSection identificationModule nctId: NCT06283654, orgStudyIdInfo id: VUmc 2018.539, briefTitle: Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation, acronym: relievED, statusModule overallStatus: COMPLETED, startDateStruct date: 2018-09-30, primaryCompletionDateStruct date: 2021-09-30, completionDateStruct date: 2023-01-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Amsterdam UMC, location VUmc, class: OTHER, descriptionModule briefSummary: In this study, the researchers explored a new approach to manage atrial fibrillation, a disease that affects millions worldwide. The goal was to see if using a simple handheld ECG device for monitoring heart rhythm could help patients avoid unnecessary visits to the emergency department (ED) after undergoing a common procedure known as pulmonary vein isolation (PVI). This procedure is often used to treat AF, but following it patients frequently visit the ED due to concerns about their heart rhythm, which can strain healthcare resources. The researchers proved a group of patients with a 1-lead ECG device, which allowed users to check their heart rhythm at any time. The researchers compared the ED utilization over a year with that of patients who received standard care after PVI. The hope was that by using the 1-lead ECG device, patients could better manage their condition from home and only seek medical help when truly necessary., conditionsModule conditions: Atrial Fibrillation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 204, type: ACTUAL, armsInterventionsModule interventions name: 1-lead ECG, outcomesModule primaryOutcomes measure: number of ED visits, secondaryOutcomes measure: ratio of the number of cardioversions emergency vs planned, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Amsterdam UMC -vumc, city: Amsterdam, country: Netherlands, geoPoint lat: 52.37403, lon: 4.88969, hasResults: False
protocolSection identificationModule nctId: NCT06283615, orgStudyIdInfo id: 2024-01-01, briefTitle: Effect of Vitamin D on Skeletal Muscle Function and Qol in Patients With Chronic Intestinal Failure/Insufficiency, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-12, primaryCompletionDateStruct date: 2024-11-30, completionDateStruct date: 2024-11-30, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-22, sponsorCollaboratorsModule leadSponsor name: Jinling Hospital, China, class: OTHER, descriptionModule briefSummary: Eligible patients were randomized into two groups: Vitamin D group and Control group. Control group: routine treatment only, no additional vitamin D intervention therapy. Vitamin D group: In addition to the conventional treatment, additional intramuscular injection of vitamin D2 was given once every two weeks, each dose of 600,000 units, and the treatment lasted for 12 weeks.The primary and secondary outcomes will be collected., conditionsModule conditions: Intestinal Failure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 84, type: ESTIMATED, armsInterventionsModule interventions name: Vitamin D, outcomesModule primaryOutcomes measure: Quality of life score, primaryOutcomes measure: Muscle function status, secondaryOutcomes measure: Serum vitamin D levels, secondaryOutcomes measure: Hepatic and renal function, secondaryOutcomes measure: Bone mineral density, secondaryOutcomes measure: Thyroid and parathyroid-related hormones, secondaryOutcomes measure: Nutritional status indicators, secondaryOutcomes measure: Number of participants with treatment-related adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Xinying Wang, status: RECRUITING, city: Nanning, state: Jiangsu, zip: 210002, country: China, contacts name: Xinying Wang, MD, role: CONTACT, phone: +86 13913028866, email: wangxinying@nju.edu.cn, contacts name: Xuejin Gao, MD, role: CONTACT, phone: +86 18251937684, email: 547625433@qq.com, contacts name: Xinying Wang, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Xuejin Gao, MD, role: SUB_INVESTIGATOR, geoPoint lat: 22.81667, lon: 108.31667, hasResults: False
protocolSection identificationModule nctId: NCT06283602, orgStudyIdInfo id: 2020/17, briefTitle: Oral Health in Children and Adolescents With Obesity and Normal Weight, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-01-01, primaryCompletionDateStruct date: 2021-03-05, completionDateStruct date: 2021-04-29, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Kahramanmaras Sutcu Imam University, class: OTHER, descriptionModule briefSummary: We aimed to compare the oral health status (dmft/DMFT index, IDCAS-II, BEWE, plaque index, gingival index, probing depth) between normal-weight (NW) and obese (OW) children/adolescents.82 participants aged 6-16 years were concluded in this cross-sectional study. The children/adolescents were classified according to the body mass index (BMI): NW (n=41) and OW (n=41). Caries experience was assessed by the International Caries Detection and Assessment System (ICDAS-II), decay, missing, filling teeth (dmft) for the primary teeth and (DMFT) for the permanent teeth, erosive tooth wear using Basic Erosive Wear Examination (BEWE), Plaque Index (PI) and Gingival Index (GI), Probing Depth (PD)., conditionsModule conditions: Pediatric Obesity, conditions: Pediatric Dentistry, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 82, type: ACTUAL, armsInterventionsModule interventions name: oral health status, outcomesModule primaryOutcomes measure: the results of DMFT, plaque and gingival indies, primaryOutcomes measure: the results of dmft, BEWE, ICDAS-II, probing dept, primaryOutcomes measure: Comparison of demographic attributes between obese and normal weights, secondaryOutcomes measure: biochemical parameters of obese individuals, secondaryOutcomes measure: other biochemical parameters of obese individuals, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 16 Years, stdAges: CHILD, contactsLocationsModule locations facility: Aslı Soğukpınar Önsüren, city: Mersin, country: Turkey, geoPoint lat: 36.79526, lon: 34.61792, hasResults: False
protocolSection identificationModule nctId: NCT06283589, orgStudyIdInfo id: INZ701-401, briefTitle: The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-12, primaryCompletionDateStruct date: 2024-07-19, completionDateStruct date: 2024-08-19, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Inozyme Pharma, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to determine if multiple doses of INZ-701, given once per week over 4 weeks are safe and increase pyrophosphate (PPi) levels in hemodialysis-dependent (HD) end stage kidney disease (ESKD) study participants who have low PPi levels. In addition, the effect of hemodialysis on the PK of INZ-701 and PPi levels will be evaluated., conditionsModule conditions: Calciphylaxis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: The SEAPORT 1 (INZ701-401) study is a Phase 1, open-label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of multiple doses of INZ-701, given once per week over 4 weeks, in study participants with end-stage kidney disease undergoing hemodialysis., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: INZ-701, outcomesModule primaryOutcomes measure: Determine if INZ-701 increases PPi levels, secondaryOutcomes measure: Assess the Time to Maximum Serum Concentration (Tmax), secondaryOutcomes measure: Assess the Maximum Serum Concentration (Cmax) of INZ-701, secondaryOutcomes measure: Assess the Area under the concentration-time curve over the dosing interval (AUCtau), secondaryOutcomes measure: Assess the Clearance after extravascular administration of drug (CL/F), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 69 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: South Florida Nephrology Research, status: RECRUITING, city: Coral Springs, state: Florida, zip: 33071, country: United States, contacts name: Ashgar Chaudhry, MD, role: CONTACT, phone: 954-510-7620, email: info@flkidney.com, geoPoint lat: 26.27119, lon: -80.2706, locations facility: Elixia Health, status: RECRUITING, city: Hollywood, state: Florida, zip: 33024, country: United States, contacts name: Steven Zeig, role: CONTACT, phone: 954-900-1101, email: info@elixiacrc.com, geoPoint lat: 26.0112, lon: -80.14949, hasResults: False
protocolSection identificationModule nctId: NCT06283576, orgStudyIdInfo id: PANCAID-00-08, briefTitle: Pancreatic Cancer Initial Detection Via Liquid Biopsy, acronym: PANCAID, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2027-12-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Karolinska University Hospital, class: OTHER, collaborators name: Umeå University, descriptionModule briefSummary: The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient cohorts. For the entire series of these studies, the following groups are planned: 1) Histologically proven early-stage pancreatic cancer (e.g. T1a/b and T2 carcinomas \[N0M0\]); 2) Intraductal papillary mucinous neoplasia (IPMN) that were operated with verification of the benign, premalignant or malignant histology; 3) ordinary branched-duct IPMN; 4) individuals at risk (IAR) with and without IPMN, with and without known hereditary cancer gene (e.g. BRCA2); 5) a high risk group of patients with chronic pancreatitis, aged 55-65, who are heavy smokers (≥40 PY), with newly onset diabetes mellitus (NODM)., conditionsModule conditions: Pancreatic Cancer, conditions: IPMN, Pancreatic, conditions: Individuals at Risk, conditions: Chronic Pancreatitis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Liquid biopsy, outcomesModule primaryOutcomes measure: Cancer detection, secondaryOutcomes measure: Overall survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Gastrocentrum, KarolinskaUniversity Hospital, city: Stockholm, zip: 14186, country: Sweden, geoPoint lat: 59.33258, lon: 18.0649, hasResults: False
protocolSection identificationModule nctId: NCT06283563, orgStudyIdInfo id: 2023/5474, briefTitle: Online Physical Activity Tracking in Patients With Multiple Sclerosis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-28, primaryCompletionDateStruct date: 2025-02-15, completionDateStruct date: 2025-02-28, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Inonu University, class: OTHER, descriptionModule briefSummary: This study aims to investigate the effects of regular remote monitoring of physical activity levels of individuals with multiple sclerosis on physical activity levels, psychological health, fatigue and quality of life., conditionsModule conditions: Multiple Sclerosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Physical activity tracking, interventions name: No physical activity tracking, outcomesModule primaryOutcomes measure: Smartphone pedometer, primaryOutcomes measure: Smartphone pedometer, primaryOutcomes measure: International Physical Activity Questionnaire - Short Form, primaryOutcomes measure: International Physical Activity Questionnaire - Short Form, secondaryOutcomes measure: Beck Depression Inventory II, secondaryOutcomes measure: Beck Depression Inventory II, secondaryOutcomes measure: Beck Anxiety Inventory, secondaryOutcomes measure: Beck Anxiety Inventory, secondaryOutcomes measure: Fatigue Severity Scale, secondaryOutcomes measure: Fatigue Severity Scale, secondaryOutcomes measure: Multiple Sclerosis Quality of Life-54, secondaryOutcomes measure: Multiple Sclerosis Quality of Life-54, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06283550, orgStudyIdInfo id: INNO-6052, briefTitle: Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-08, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Innovaderm Research Inc., class: OTHER, descriptionModule briefSummary: This study aims to evaluate the safety, efficacy and tolerability of abrocitinib in subjects with moderate to severe chronic hand eczema, and its effects on skin biomarkers using a noninvasive method of tape stripping., conditionsModule conditions: Chronic Hand Eczema, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 84, type: ESTIMATED, armsInterventionsModule interventions name: Abrocitinib 200 mg, interventions name: Abrocitinib 100 mg, interventions name: Placebo, outcomesModule primaryOutcomes measure: Change from baseline in hand modified Total Lesion Symptom Score (mTLSS), secondaryOutcomes measure: Change from baseline in hand modified Total Lesion Symptom Score (mTLSS), secondaryOutcomes measure: Reduction from baseline in hand Physician's Global Assessment (PGA), secondaryOutcomes measure: Change from baseline in Hand Eczema Severity Index (HECSI), secondaryOutcomes measure: Change from baseline in Extent of Disease affected with moderate to severe chronic hand eczema (CHE), secondaryOutcomes measure: Patient Global Assessment (PaGA) measurements, secondaryOutcomes measure: Change from baseline in hand Dermatology Life Quality Index (DLQI), secondaryOutcomes measure: Change from baseline in Quality of Life in Hand Eczema Questionnaire (QOLHEQ), secondaryOutcomes measure: Change from baseline in pain Numerical Rating Scale (NRS), secondaryOutcomes measure: Change from baseline in itch Numerical Rating Scale (NRS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Innovaderm Research Inc., city: Montréal, state: Quebec, zip: H2X 2V1, country: Canada, contacts name: Rosanna Ottoni, BSc, role: CONTACT, phone: 514-521-4285, phoneExt: 107, email: rottoni@innovaderm.com, geoPoint lat: 45.50884, lon: -73.58781, hasResults: False
protocolSection identificationModule nctId: NCT06283537, orgStudyIdInfo id: KÜBAP-01/2023-39, briefTitle: Online Episiotomy Simulation Training for Midwifery Students, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-05-30, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Kastamonu University, class: OTHER, descriptionModule briefSummary: Purpose: To determine the effect of online episiotomy simulation training to midwifery students on their episiotomy application skills, satisfaction with the teaching method and self-confidence.Method: This study is a randomized controlled experimental study. It will be conducted with third-year students studying at Kastamonu University Midwifery Department in the 2023-2024 period. In the research, all third-year students in the midwifery department (n=60) will be divided into 30 students into the online education group and 30 students into the face-to-face education group using a random sampling model. "Student Information Form", "Episiotomy Skill Evaluation Form" and "Student Satisfaction and Self-Confidence in Learning Scale" will be used to collect data., conditionsModule conditions: Training Group, Sensitivity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A comparative randomized controlled trial, primaryPurpose: OTHER, maskingInfo masking: SINGLE, maskingDescription: After all students in the face-to-face education and online education groups complete their applications, the students will practice on the material one by one in the school environment and will be evaluated through the Episiotomy Skill Evaluation Form. In the evaluation, a blinding technique will be used to prevent the person conducting the study interventions from making an evaluation in favor of the intervention group. For this purpose, the faculty member conducting the research initiatives will not take part in the evaluation, instead the evaluation will be made by two different field experts. The experts to be consulted for the evaluation will consist of people working as academicians in the field of obstetrics, nursing and midwifery. After the evaluation, students will have to fill out the survey (Student Information Form) and scale (Student Satisfaction and Self-Confidence in Learning Scale)., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Effect of training method, outcomesModule primaryOutcomes measure: episiotomy skill performances, secondaryOutcomes measure: Satisfaction with education, otherOutcomes measure: Self-confidence in learning, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False